ARCT Projected Dividend Yield

Arcturus Therapeutics Holdings Inc ( NASDAQ : ARCT )

Arcturus Therapeutics Holdings is a clinical -stage messenger RNA medicines and vaccine company focused on the development of infectious disease vaccines and other opportunities within liver and respiratory rare diseases. Co.'s initial COVID-19 vaccine candidate, ARCT-021, was designed to promote immune responses to the spike protein of the Severe Acute Respiratory Syndrome-2 virus, which is the part of the virus that allows infection to occur. The LUNAR-OTC development program addresses ornithine transcarbamylase (OTC) deficiency, a genetic disease caused by mutations in the OTC gene that lead to dysfunctional or deficient OTC. The LUNAR-CF program addresses cystic fibrosis lung disease.

20 YEAR PERFORMANCE RESULTS